Description

Insulet’s Next Big Test — Fixing Omnipod’s Type 2 Retention Gap!

Insulet Corporation reported its second quarter 2026 financial results, demonstrating a continued trajectory of strong revenue growth, expanded profitability, and solid cash flow generation. Total revenue reached $802 million, reflecting a 23% increase year-over-year on a constant currency basis. Growth was driven by robust demand for the Omnipod insulin management system across both U.S. and international markets, with international revenue rising over 33% and U.S. Omnipod revenue up 20%. The company also benefited from favorable price and product mix, alongside increased manufacturing productivity, contributing to an adjusted gross margin of 72.9%, up 320 basis points from the prior year. Operating expenses increased in line with investments in research and development and commercial expansion, including a larger U.S. sales force and enhanced customer support programs. Despite these investments, adjusted operating margin improved by 140 basis points to 19.3%, and adjusted earnings per share rose 41.5% to $1.